MARC Record from marc_columbia

LEADER: 07849cam a2200361 a 4500
001 6925108
005 20221130191918.0
008 081017s2008 nyu 000 0 eng
015 $aGBA786042$2bnb
016 7 $a014199639$2Uk
020 $a9780387483436 (hbk.)
020 $a0387483438 (hbk.)
035 $a(OCoLC)ocn166372327
035 $a(OCoLC)166372327
035 $a(NNC)6925108
035 $a6925108
040 $aUKM$cUKM$dBTCTA$dYDXCP$dBAKER$dOCLCG$dCDX$dNNC$dOrLoB-B
050 4 $aHD9999.B442$bH36 2008
082 04 $a338.476606$222
245 00 $aHandbook of bioentrepreneurship /$cedited by Holger Palzelt, Thomas Brenner.
260 $aNew York ;$aLondon :$bSpringer,$c2008.
263 $a200802
300 $axiii, 294 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aInternational handbook series on entrepreneurship ;$vv. 4
505 00 $g1.$tIntroduction to the Handbook of Bioentrepreneurship /$rHolger Patzelt and Thomas Brenner -- $g2.$tBiotechnology Dynamics at the Global Scale /$rPhilip Cooke -- $g2.1.$tIntroduction -- $g2.2.$tThe Global Health Care Market in Relation to Biotechnology -- $g2.3.$tGlobal Bioregions -- $g2.4.$tThe World Leaders in Brief: Top Bioclusters in the USA -- $g2.5.$tComparison of UK and German Clusters -- $g2.6.$tBioregions and Their Key Characteristics Elsewhere -- $g2.6.1.$tEconomic Geography of Clusters Spawned by Pharmaceuticals Firms -- $g2.6.2.$tThe Research and DBF-led Clusters in Israel and Canada -- $g2.7.$tConclusions -- $g3.$tGeographic Clustering in Biotechnology: Social Networks and Firm Foundings /$rDirk Fornahl and Olav Sorenson -- $g3.1.$tIntroduction -- $g3.2.$tSocial Networks and Geographic Proximity -- $g3.3.$tSocial Networks and Entrepreneurship -- $g3.3.1.$tOpportunity Perception -- $g3.3.2.$tIntellectual Capital -- $g3.3.3.$tHuman Capital -- $g3.3.4.$tFinancial Capital -- $g3.4.$tImplications and Evidence -- $g3.5.$tPolicy Implications -- $g3.6.$tSummary and Outlook -- $g4.$tInnovation Networks in Biotechnology /$rPier Paolo Saviotti and David Catherine -- $g4.1.$tIntroduction -- $g4.2.$tThe Nature of Innovation Networks -- $g4.2.1.$tThe Entry of New Firms -- $g4.2.2.$tBiotechnology -- $g4.2.3.$tThe Changing Role of Universities -- $g4.2.4.$tTheories of Industrial Organization -- $g4.2.5.$tInnovation Networks -- $g4.3.$tRecent Developments in Network Dynamics -- $g4.4.$tSummary and Conclusions -- $g5.$tStrategy and Strategic Thinking in Biotechnology Entrepreneurship /$rAlan L. Carsrud, Malin Brannback and Maija Renko -- $g5.1.$tIntroduction -- $g5.2.$tSector Development Review -- $g5.3.$tInnovation in Biotechnology -- $g5.4.$tTheoretical Bases for Entrepreneurial Biotechnology -- $g5.5.$tStrategic Management, Entrepreneurship, and Biotechnology -- $g5.6.$tStrategy Components in Early-Stage Biotechnology Firms -- $g5.6.1.$tProactiveness -- $g5.6.2.$tFit -- $g5.6.3.$tReactiveness -- $g5.6.4.$tTraditions and History -- $g5.7.$tDiscussion and Conclusions -- $g6.$tResearch on Strategic Alliances in Biotechnology: An Assessment and Review /$rMaxim Sytch and Philipp Bubenzer -- $g6.1.$tIntroduction -- $g6.2.$tWhy and with Whom Do Biotechnology Firms Form Alliances? -- $g6.2.1.$tAccess to Knowledge and Other Complementary Resources -- $g6.2.2.$tPursuit of Legitimacy -- $g6.2.3.$tChoosing Partners -- $g6.3.$tGovernance of Alliances -- $g6.4.$tConsequences of Alliances -- $g6.4.1.$tConsequences of Accessing Knowledge and Other Complementary Resources -- $g6.4.2.$tConsequences of Enhancing Legitimacy -- $g6.4.3.$tTaking Off the Rose-Colored Glasses: Alliances as Relational Liability -- $g6.5.$tFuture Research -- $g7.$tMergers and Acquisitions in the Biotechnology Industry /$rLars Schweizer and Dodo zu Knyphausen-Aufsess -- $g7.1.$tIntroduction -- $g7.2.$tDevelopment of the Biotechnology Industry and the Need for M&A -- $g7.2.1.$tThe Development of the Biotechnology Industry from a Scientific Perspective -- $g7.2.2.$tThe Development of the Biotechnology Industry from an Organizational Perspective -- $g7.2.3.$tThe Development of the Biotechnology Industry from a Financial Perspective -- $g7.3.$tLayers of M&A Activities -- $g7.3.1.$tM&A Activities Among Biotechnology Companies -- $g7.3.2.$tM&A Activities Between Pharmaceutical and Biotechnology Companies -- $g7.4.$tSummary and Future Research -- $g8.$tSynergy, Strategy and Serendipity: Kirin Brewery's Entry into Biopharmaceuticals /$rMichael J. Lynskey -- $g8.1.$tIntroduction -- $g8.2.$tThe Locus of Entrepreneurship -- $g8.3.$tBackground -- $g8.4.$tSynergy -- $g8.4.1.$tOpportunity Recognition -- $g8.4.2.$tEarly Efforts with Erythropoietin -- $g8.4.3.$tImportance of Tacit Knowledge -- $g8.4.4.$tScientific Gatekeepers and Academic Collaboration -- $g8.5.$tSerendipity -- $g8.5.1.$tOrigins of the Alliance with Amgen -- $g8.5.2.$tStructure of the Joint Venture -- $g8.5.3.$tKirin's Contributions and Manufacturing Scale-Up -- $g8.5.4.$tOutcome of the Joint Venture -- $g8.5.5.$tKey Success Factors -- $g8.6.$tStrategy -- $g8.6.1.$tTargeting Niche Therapeutic Fields -- $g8.6.2.$tCell Therapy and Stem Cell Research -- $g8.6.3.$tMonoclonal Antibodies and the Transgenic Mouse -- $g8.7.$tConclusions -- $g9.$tA Survey Review of University Biotechnology and Entrepreneurship Commercialization /$rDavid B. Audretsch, T. Taylor Aldridge and Marcus Perry -- $g9.1.$tIntroduction -- $g9.2.$tCommercialization of Science and Entrepreneurial Choice -- $g9.3.$tScientist Biotech Entrepreneurship -- $g9.4.$tConclusions -- $g10.$tUniversity-Based Biotechnology Spin-Offs /$rAmalya L. Oliver -- $g10.1.$tIntroduction -- $g10.1.1.$tThe Context of the Biotechnology Industry -- $g10.1.2.$tEntrepreneurial Universities -- $g10.2.$tScientific Entrepreneurship -- $g10.2.1.$tChanges in Academic Science -- $g10.3.$tUniversity Spin-Offs and University-Based Spin-Offs -- $g10.3.1.$tUniversity-Based Spin-Offs as a New Organizational Form -- $g10.3.2.$tLevels of Analysis of USOs and USBOs -- $g10.3.3.$tA Life Cycle Approach to USOs -- $g10.4.$tIntegration, Complexities and New Research Directions -- $g11.$tPatenting Biotechnology /$rSaradindu Bhaduri -- $g11.1.$tIntroduction -- $g11.2.$tBiotechnology Industry: Meaning and Scope -- $g11.2.1.$tGenetic Engineering: Basic Features -- $g11.2.2.$tGenetic Engineering: Continuity or Discontinuity? -- $g11.3.$tPatents: An Overview -- $g11.3.1.$tBasic Issues -- $g11.3.2.$tEvolution of Patents in Biotechnology -- $g11.4.$tPatenting Biotechnology: Implications -- $g11.4.1.$tPatenting Life Forms and 'Ordre Public': Basic Issues and Inter-country Comparison -- $g11.4.2.$tImplications of Patent Length -- $g11.4.3.$tImplications of Patent Scope -- $g11.4.4.$tBenefit Sharing: 'Bio-Diversity' vis-a-vis 'Indigenous Science' -- $g11.5.$tConclusion -- $g12.$tLegal Frameworks and Public Support in the Biotechnology Industry /$rDirk Engel and Oliver Heneric -- $g12.1.$tIntroduction -- $g12.2.$tLegal Framework and Public Support: Rationales and Economic Relevance -- $g12.2.1.$tRationales for Public Support and a Legal Framework -- $g12.2.2.$tThe Impact of Public R&D Funding: Empirical Findings -- $g12.2.3.$tEvidence Concerning the Impact of Legal Framework Changes -- $g12.3.$tLegal Framework Changes in Germany -- $g12.4.$tAn Empirical Assessment of the Contribution of Legal Framework Change -- $g12.5.$tFuture Research and Concluding Remarks.
650 0 $aBiotechnology industries$xManagement.
650 0 $aEntrepreneurship.$0http://id.loc.gov/authorities/subjects/sh85044149
700 1 $aPalzelt, Holger.
700 1 $aBrenner, Thomas,$d1968-$0http://id.loc.gov/authorities/names/n99021161
830 0 $aInternational handbook series on entrepreneurship ;$vv. 4.$0http://id.loc.gov/authorities/names/n2003109168
852 00 $boff,bus$hHD9999.B442$iH36 2008g